Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 

The NCI Predoctoral to Postdoctoral Fellow Transition Award

The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers.

Application Deadline: February 22, 2019

Leveraging Health Information Technology (Health IT) to Address Minority Health and Health Disparities (R01 Clinical Trial Optional)

This FOA seeks to support research that examines how health information technology adoption impacts minority health and health disparity populations in access to care, quality of care, patient engagement, and health outcomes.

Application Deadlin e: March 1, 2019
Learn more about the Health IT R01>>

Yale Scholars in Implementation Science (YSIS) Career Development Program

The YSIS Career Development Program is an NIH-funded K12 program within the Yale Center for Implementation Science at the Yale School of Medicine. Funded by the NIH’s National Heart, Lung, and Blood Institute, it is designed to train junior faculty and postdoctoral fellows late-stage dissemination and implementation science.

Application Deadline: March 1, 2019

Department of Defense Breast Cancer Research Program Funding Opportunities

These funding opps are to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public.  

Breakthrough Award – Level 1 & 2: The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. Letter of Intent Due: March 14, 2019
Breakthrough Fellowship Award: The Fellowship Award supports recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research during their postdoctoral fellowship. Letter of Intent Due: March 14, 2019
Era of Hope Scholar Award: The Era of Hope Scholar Award supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer. Letter of Intent Due: March 14, 2019
Innovator Award: The Innovator Award supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer. Preproposal Due: March 12, 2019
Distinguished Investigator Award: The Distinguished Investigator Award enables established visionary leaders from any field to pursue innovative ideas that could accelerate progress toward ending breast cancer. Preproposal Due: March 12, 2019

Sontag Foundation  Distinguished Scientist Award

The DSA seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.

Application Deadline: March 13, 2019

Damon Runyon Cancer Research Foundation Fellowship Award

The Foundation encourages all theoretical and experimental research relevant to the study of cancer and the search for cancer causes, mechanisms, therapies and prevention. Awards are made to institutions for the support of the Fellow under direct supervision of the Sponsor.

Application Deadline: March 15, 2019

NCCN Preclinical and Clinical Studies of CDK4 and 6 Inhibition with Abemaciclib for Breast Cancers

NCCN has received a $2 million research grant from Eli Lilly and Company to support the performance of preclinical, clinical and correlative studies of abemaciclib in the treatment of breast cancer.

RFP Due: March 22, 2019

Charles H. Hood Foundation Child Health Research Awards Program

The intent of this Award is to support newly independent faculty, provide the opportunity to demonstrate creativity, and assist in the transition to other sources of funding. Research projects must have direct relevance to child health.

Application Deadline: March 28, 2019 

NCI Awardee Skills Development Consortium: Research Education Short Courses (UE5)

The overarching goal of this NCI UE5 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical cancer research needs.

Application Deadline: April 1, 2019

Learn more about the NCI Skill Development Courses>>

Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care (R43/R44)

This FOA encourages Small Business Innovation Research grant applications from small business concerns proposing research for commercial development of novel cancer-relevant technologies.

Application Deadline: April 5, 2019

View the SBIR grant application>>

Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R43/R44)

This FOA encourages Small Business Innovation Research grant applications from small business concerns proposing commercially-directed research for the development of cancer prevention, diagnosis, or treatment technologies to improve cancer outcomes in low- and middle-income countries, and low-resource settings in the US.

Application Deadline: April 5, 2019

Request for Information to Better Facilitate Cancer Systems Epidemiology Research

The NCI seeks broad input from members of the scientific community to identify areas of need and opportunities for interdisciplinary, systems science research focused on cancer risk and prognosis, particularly data analysis and interpretation when applying comprehensive analytical approaches, such as systems or computational modeling, to study of the etiology of cancer.  

Response Date: April 30 , 2019

Biology of Bladder Cancer (R01/R21)

This FOA encourages applications investigating the biology and underlying mechanisms of bladder cancer.

Application Deadlines: (R01): June 5, 2019 (R21): June 16, 2019

Tobacco Regulatory Science (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

Estimated Application Due Date: July 19, 2019

Provocative Questions (PQs) in Cancer with an Underlying HIV Infection (R01 Clinical Trial Optional)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 1, 2019

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants. 

Current opportunities are listed below. 

View a full list of grant opportunities available throughout the year>> 

American Cancer Society Institutional Research Grant

We are pleased to offer this ACS Institutional Research Grant pilot funding opportunity to Yale Assistant Professors to support innovative work in the broad fields of basic, translational, clinical and population prevention/control cancer research.

Application Deadline: March 1, 2019

2019 YCC Pilot Internal Grants 

Yale Cancer Center is pleased to announce the 2019 Pilot Internal Grants competition. These grants will support innovative basic, clinical, computational, population and epidemiology, prevention/control, and translational cancer research.

Submission Deadline: March 3, 2019

Luminary Award of Excellence

The YNHH Smilow Luminary Award of Excellence will serve to recognize, and ceremoniously acknowledge, those individuals and/or teams who consistently exceed performance expectations and deliver high quality cancer care for our patients, families and the health system through community service, optimization/ innovative solutions, patient experience, leadership and research initiatives. Nominations should be submitted directly to